to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
A Phase I, Open-label, Dose-escalation Study to Determine the Maximum Tolerance Dose (MTD) and to Evaluate the Safety of 188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage.
Sponsor: National Atomic Research Institute, Taiwan
Terminated
Some concerns arose for the accumulation of radioactivity in liver and spleen.
This PHASE1 trial investigates Tumors and is currently terminated or withdrawn. National Atomic Research Institute, Taiwan leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jan 2024 [monthly]
Terminated PHASE1
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2020 [monthly]
Unknown Status PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE1
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Atomic Research Institute, Taiwan
For direct contact, visit the study record on ClinicalTrials.gov .